適切に管理されたワーファリン、やはり
Safety of Switching From a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial.
Mentions
Extended reach
Total likes
Video views
Mentions per month
Aug 2023 – Sep 2025Where it's discussed
-
X / Twitter220 posts
-
News18 articles
-
YouTube3 videos
-
Bluesky1 posts
AI synopsis
What people are saying
The discussions emphasize the potential risks linked to switching anticoagulants in frail older patients, with phrases like 'more bleeding complications' and questions about safety, tone, and methodology indicating cautious skepticism. Some examples highlight the importance of careful patient evaluation and whether the findings should influence clinical decisions, reflecting a focus on clinical relevance and debate.
Most discussions highlight concerns or skepticism about switching, especially due to increased bleeding risks, reflecting a cautious stance rather than full agreement.
The topic generated moderate interest, with comments on the safety, methodology, and clinical implications, but not overwhelming enthusiasm.
Participants referenced detailed results, discussed implications, and questioned methodology, showing active but not deeply complex engagement.
Overall, the discussions seem to reinforce clinical caution but don’t appear to drive immediate change in practice or policies significantly.
Abstract in brief
- This study investigated whether switching frail older patients with atrial fibrillation from vitamin K antagonists (VKAs) to non-vitamin K oral anticoagulants (NOACs) is safe and effective.
- The trial included patients around 83 years old with high frailty scores and followed them over 12 months to compare bleeding complications and thromboembolic events between those who switched to NOACs and those who continued VKAs.
- The results showed no significant benefit in switching, with a similar or slightly higher risk of bleeding in the NOAC group, leading to the trial being stopped early for futility.]
Top posts
Most liked on X and BlueskyThe randomized controlled trial Frail Atrial Fibrillation (#FRAIL-AF) showed that switching from vitamin K antagonists #VKA to non-vitamin K oral anticoagulant #NOAC in frail older patients with AF was associated with more bleeding complications https://t.co/S1Q1nIcxoM https://t.co/x6RYs1YHf7
Switching frail elderly patients from VKA antagonists to DOACs resulted in a significantly higher rate of bleeding. Dutch RCT published in @circulation. https://t.co/iEoDlVgr7V https://t.co/NRVLp4BTdS
¿Son los > 80 años "especiales" a la hora de ANTICOAGULAR en #fibrilaciónauricular? Pues sí lo parece. La opción de los antivitamina K ha considerar como prioritaria (Frail-AF) https://t.co/qSKTt0EzC4 y edoxaban se suma a la reducción de dosis por edad https://t.co/8F0iRkw2LZ https://t.co/M703XwnVLM
【フレイル高齢者の抗凝固:VKA→NOAC切替え】 フレイル高齢AF 1330患者を、 (平均83歳、Groningen Frailty Indicator score中央値4/除外:cCr<30,弁膜症性AF) 1⃣VKA→NOAC切替2⃣VKA継続 に割付 1⃣は2⃣と比べ ✅出血性合併症の増加 ✅血栓塞栓症は減少させない 【FRAIL-AF】https://t.co/pjyqSASvtG https://t.co/GWB5sGmypZ
JCでのまとめをつらつら。 これまでの、各DOACのlandmark study結果から、出血の観点から「DOAC>VKA」という流れは間違いない。 しかし、実臨床やっていると、フレイリティの高い高齢A-fib患者の抗凝固って困る。過去のRCTでは除外されているポピュレーション #循薬ネット https://t.co/ox4ew2zVjl https://t.co/ZF5NFOv0Em
All mentions
2023 Nephrology and Hypertensiology Advances by Leading Experts
In this review of 2023, experts discuss the top nephrological and hypertensiological studies, including the impact of high-efficiency hemodiafiltration on mortality and the safety of anticoagulant switching in frail…
Anticoagulation Strategies for Atrial Fibrillation Patients at Risk of Stroke
Dr Sander van Doorn and Dr Christian Ruff discuss current and future treatment options for stroke prevention in atrial fibrillation patients, focusing on FRAILAF and AZALEA studies exploring anticoagulation therapies…
Weekly Review of Cardiology Developments and Studies
This week in cardiology, we discuss listener feedback on SURPASS CVOT ablation limits and recent FDA alerts regarding the Watchman device. Join Dr. John Mandola as he covers oral anticoagulation options for elderly…
Safety of Switching from VKAs to NOACs in Frail Older Atrial Fibrillation Patients
This study investigated whether switching frail older patients with atrial fibrillation from vitamin K antagonists to non-vitamin K oral anticoagulants is safe and effective. The trial included patients around 83 years…
心房細動に対してビタミンK拮抗薬(VKA)で管理されている虚弱高齢者で、DOAC(NOAC)への切替えが安全に可能かを確かめた研究 ・対象は75歳以上、かつGroningen frailty indicatorスコア≧3の虚弱高齢者 ・eGFR<30の患者や弁膜症性心房細動の患者は除外 https://t.co/ff8ekxQ1fG
Umstellen, gerade im höheren Alter, scheint nicht ganz trivial zu sein (pubmed.ncbi.nlm.nih.gov/37634130/). Allerdings sind im Vergleich DOAKs schon überzeugender, siehe zB. ARISTOTLE (www.nejm.org/doi/pdf/10.1...).
1. https://t.co/cPgNPcAHw4 2. https://t.co/zyZSTJLixN 3. https://t.co/mouYm7Rz3E 4. https://t.co/6QvXhBvEPp 5. https://t.co/DjmSDlzazE 6. https://t.co/AwbRdVjVYy 7. https://t.co/D1gzJbxE5u
Muy interesante! Pero parece que no debería ser tan automático el cambio: https://t.co/phGf022Oiq https://t.co/fyeuHZiIhE
De acuerdo con un estudio pragmático abierto; esta conducta se asocia a un mayor riesgo de sangrado. Para mi un resultado inesperado pues uno piensa que al simplificar régimen menos sangrado. ¿Ustedes qué piensan? Estudio: https://t.co/phGf022Oiq
Circulation。フレイル高齢者の心房細動に対する抗凝固療法変更の効果を検討するRCT https://t.co/l6gYrH4gtt
Letter by Millis et al Regarding Article, “Safety of Switching From a Vitamin K Antagonist to a Non–Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial” https://t.co/hzuVYCNrLv
Letter by Kohsaka et al Regarding Article, “Safety of Switching From a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial” https://t.co/rtxCAgjIRE
RT @Luis_Corral_Gud: ¿Son los > 80 años "especiales" a la hora de ANTICOAGULAR en #fibrilaciónauricular? Pues sí lo parece. La opción de l…
RT @Luis_Corral_Gud: ¿Son los > 80 años "especiales" a la hora de ANTICOAGULAR en #fibrilaciónauricular? Pues sí lo parece. La opción de l…
RT @Luis_Corral_Gud: ¿Son los > 80 años "especiales" a la hora de ANTICOAGULAR en #fibrilaciónauricular? Pues sí lo parece. La opción de l…
RT @Luis_Corral_Gud: ¿Son los > 80 años "especiales" a la hora de ANTICOAGULAR en #fibrilaciónauricular? Pues sí lo parece. La opción de l…
Letter by Ko et al Regarding Article, “Safety of Switching From a Vitamin K Antagonist to a Non–Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial” https://t.co/VpS3PqOar6
RT @Luis_Corral_Gud: ¿Son los > 80 años "especiales" a la hora de ANTICOAGULAR en #fibrilaciónauricular? Pues sí lo parece. La opción de l…
RT @Luis_Corral_Gud: ¿Son los > 80 años "especiales" a la hora de ANTICOAGULAR en #fibrilaciónauricular? Pues sí lo parece. La opción de l…
RT @Luis_Corral_Gud: ¿Son los > 80 años "especiales" a la hora de ANTICOAGULAR en #fibrilaciónauricular? Pues sí lo parece. La opción de l…
RT @Luis_Corral_Gud: ¿Son los > 80 años "especiales" a la hora de ANTICOAGULAR en #fibrilaciónauricular? Pues sí lo parece. La opción de l…
RT @Luis_Corral_Gud: ¿Son los > 80 años "especiales" a la hora de ANTICOAGULAR en #fibrilaciónauricular? Pues sí lo parece. La opción de l…
RT @Luis_Corral_Gud: ¿Son los > 80 años "especiales" a la hora de ANTICOAGULAR en #fibrilaciónauricular? Pues sí lo parece. La opción de l…
RT @Luis_Corral_Gud: ¿Son los > 80 años "especiales" a la hora de ANTICOAGULAR en #fibrilaciónauricular? Pues sí lo parece. La opción de l…
¿Son los > 80 años "especiales" a la hora de ANTICOAGULAR en #fibrilaciónauricular? Pues sí lo parece. La opción de los antivitamina K ha considerar como prioritaria (Frail-AF) https://t.co/qSKTt0EzC4 y edoxaban se suma a la reducción de dosis por edad https://t.co/8F0iRkw2LZ https://t.co/M703XwnVLM
Letter by Kohsaka et al Regarding Article “Safety of Switching From a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial”| Circulation https://t.co/FaLEmpHaf8
Safety of Switching From a Vitamin K Antagonist to a Non–Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial | Circulation https://t.co/0pmWMqeY1E
Safety of switching from a Vitamin K antagonist to a non–Vitamin K antagonist oral anticoagulant in frail older patients with atrial fibrillation https://t.co/BQ98CV3j87 https://t.co/P9XHn2VkXe
Daily recommendation #hpm FRAIL-AF RCT: Nonvalvular AF frail patients >75 years HR 1.69 for switching to an NOAC relative to continuing INR-guided VKA treatment 95% CI, 1.23–2.32; P=0.00112 https://t.co/oRbUkcCqHn https://t.co/UzR0x1nDyT
RT @RevistaMFSamfyc: Seguridad de pasar de un anticoagulante oral antagonista de vitamina K a uno no antagonista de vitamina K en pacientes…
RT @RevistaMFSamfyc: Seguridad de pasar de un anticoagulante oral antagonista de vit K a uno no antagonista de vit K en ancianos frágiles c…
Safety of Switching From a Vitamin K Antagonist to a Non–Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial https://t.co/tmYNw1bOIu https://t.co/Ti4UzQnFMU
RT @DrDavidWarriner: Free full text link here to the paper: @CircAHA https://t.co/zC7uqLYKq7
Free full text link here to the paper: @CircAHA https://t.co/zC7uqLYKq7
@fbalex19071 @vmuecke_k Sicher? Fast alle diese Studien liefen mit schlecht eingestelltem Warfarin (TTR<60%). Es gibt nur sehr wenige #doak vs Phenprocoumon Studien. FRAIL-AF ist eine (rwd) Studie, die VKA im Vorteil zeigt https://t.co/LProNiQFsE https://t.co/IlkFFWGCpU https://t.co/BzeVWcO1Dx
Seguridad de pasar de un anticoagulante oral antagonista de vitamina K a uno no antagonista de vitamina K en pacientes ancianos frágiles con fibrilación auricular: resultados del ensayo controlado aleatorizado FRAIL-AF https://t.co/inHhtvz1jB PMID 37634130
@CKD_pharmacist これなんですけど- https://t.co/ThJNq0MCQf
そして明日はこれ‼️ #MEBIUS https://t.co/TYYSf5Xh9W
And again: newer is not better when it comes to medicines. Switching INR –guided warfarin to NOAC in frail older patients with A Fib = more bleeding complications without additional benefit in thromboembolism protection. https://t.co/nhnZyeWZSB
RT @Fizz_DI: ワルファリンで治療中の虚弱高齢者(平均83歳、n=1,330)、DOACへの切替で塞栓症は減らずに出血が増えた、という報告。 ・切替 vs 継続 主要な出血:HR=1.69 [95%CI: 1.23-2.32] 血栓塞栓症:HR=1.26 [95%C…
ワルファリンで治療中の虚弱高齢者(平均83歳、n=1,330)、DOACへの切替で塞栓症は減らずに出血が増えた、という報告。 ・切替 vs 継続 主要な出血:HR=1.69 [95%CI: 1.23-2.32] 血栓塞栓症:HR=1.26 [95%CI: 0.60-2.61] Circulation.149(4):279-289,(2024) PMID:37634130 https://t.co/ptoQB0ZPJg
RT @EvidenceObasan: 適切に管理されたワーファリン、やはり
RT @EvidenceObasan: 適切に管理されたワーファリン、やはり
RT @EvidenceObasan: 適切に管理されたワーファリン、やはり
RT @EvidenceObasan: 適切に管理されたワーファリン、やはり
RT @EvidenceObasan: 適切に管理されたワーファリン、やはり
RT @EvidenceObasan: 適切に管理されたワーファリン、やはり
RT @EvidenceObasan: 適切に管理されたワーファリン、やはり
RT @EvidenceObasan: 適切に管理されたワーファリン、やはり
RT @EvidenceObasan: 適切に管理されたワーファリン、やはり
RT @EvidenceObasan: 適切に管理されたワーファリン、やはり
RT @EvidenceObasan: 適切に管理されたワーファリン、やはり
RT @EvidenceObasan: 適切に管理されたワーファリン、やはり
RT @EvidenceObasan: 適切に管理されたワーファリン、やはり
RT @EvidenceObasan: 適切に管理されたワーファリン、やはり
RT @EvidenceObasan: 適切に管理されたワーファリン、やはり
適切に管理されたワーファリン、やはり
RT @air_garcia: El cambio de tratamiento con AVK guiado por el INR a un NACO en ptes ancianos frágiles con FA se asoció con + complicacione…
RT @Medicinmanden: Supervigtigt klinisk forsøg! I dag skiftes den blodfortyndende behandling til skrøbelige ældre ofte fra ældre præparater…
Supervigtigt klinisk forsøg! I dag skiftes den blodfortyndende behandling til skrøbelige ældre ofte fra ældre præparater (VKA) til nyere (fXa-hæmmere). Dette store kliniske viser, at det skal vi stoppe med! #geriatri #dklæger #cardiology https://t.co/owcLcDf9jE
・高齢フレイル患者に対するVKA→NOACへの変更の安全性 https://t.co/sYg48h8Be7
Safety of Switching From a Vitamin K Antagonist to a Non–Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: the FRAIL-AF Trial @CircAHA
RT @pedreiramicina: En este contexto surge en el seno de la Universidad de Utrecht una pregunta razonable: ¿Será acaso más seguro emplear A…
RT @pedreiramicina: En este contexto surge en el seno de la Universidad de Utrecht una pregunta razonable: ¿Será acaso más seguro emplear A…
RT @pedreiramicina: En este contexto surge en el seno de la Universidad de Utrecht una pregunta razonable: ¿Será acaso más seguro emplear A…
El cambio de tratamiento con AVK guiado por el INR a un NACO en ptes ancianos frágiles con FA se asoció con + complicaciones hemorrágicas vs la continuación del tratamiento con AVK, sin reducción asociada de las complicaciones tromboembólicas. #segpac https://t.co/pGNZJwZ4ps
RT @rincondesisifo: (Circulation) ¿Es seguro el cambio de una cumarina a un ACOD en pacientes ancianos frágiles con FA? https://t.co/X8AQij…
RT @mameeps: 【フレイル高齢者の抗凝固:VKA→NOAC切替え】 フレイル高齢AF 1330患者を、 (平均83歳、Groningen Frailty Indicator score中央値4/除外:cCr<30,弁膜症性AF) 1⃣VKA→NOAC切替2⃣VKA継続…
RT @mameeps: 【フレイル高齢者の抗凝固:VKA→NOAC切替え】 フレイル高齢AF 1330患者を、 (平均83歳、Groningen Frailty Indicator score中央値4/除外:cCr<30,弁膜症性AF) 1⃣VKA→NOAC切替2⃣VKA継続…
RT @annabonet: Seguridad del cambio de un antagonista de la vitamina K a un anticoagulante oral no antagonista de la vitamina K en paciente…
RT @annabonet: Seguridad del cambio de un antagonista de la vitamina K a un anticoagulante oral no antagonista de la vitamina K en paciente…
RT @annabonet: Seguridad del cambio de un antagonista de la vitamina K a un anticoagulante oral no antagonista de la vitamina K en paciente…
RT @rincondesisifo: (Circulation) ¿Es seguro el cambio de una cumarina a un ACOD en pacientes ancianos frágiles con FA? https://t.co/X8AQij…
RT @mameeps: 【フレイル高齢者の抗凝固:VKA→NOAC切替え】 フレイル高齢AF 1330患者を、 (平均83歳、Groningen Frailty Indicator score中央値4/除外:cCr<30,弁膜症性AF) 1⃣VKA→NOAC切替2⃣VKA継続…
Seguridad del cambio de un antagonista de la vitamina K a un anticoagulante oral no antagonista de la vitamina K en pacientes de edad avanzada y frágiles con fibrilación auricular: Resultados del ensayo controlado aleatorizado FRAIL-AF | Circulación https://t.co/M2dc2hJITL
RT @mameeps: 【フレイル高齢者の抗凝固:VKA→NOAC切替え】 フレイル高齢AF 1330患者を、 (平均83歳、Groningen Frailty Indicator score中央値4/除外:cCr<30,弁膜症性AF) 1⃣VKA→NOAC切替2⃣VKA継続…
RT @rincondesisifo: (Circulation) ¿Es seguro el cambio de una cumarina a un ACOD en pacientes ancianos frágiles con FA? https://t.co/X8AQij…
RT @mameeps: 【フレイル高齢者の抗凝固:VKA→NOAC切替え】 フレイル高齢AF 1330患者を、 (平均83歳、Groningen Frailty Indicator score中央値4/除外:cCr<30,弁膜症性AF) 1⃣VKA→NOAC切替2⃣VKA継続…
【フレイル高齢者の抗凝固:VKA→NOAC切替え】 フレイル高齢AF 1330患者を、 (平均83歳、Groningen Frailty Indicator score中央値4/除外:cCr<30,弁膜症性AF) 1⃣VKA→NOAC切替2⃣VKA継続 に割付 1⃣は2⃣と比べ ✅出血性合併症の増加 ✅血栓塞栓症は減少させない 【FRAIL-AF】https://t.co/pjyqSASvtG https://t.co/GWB5sGmypZ
(Circulation) ¿Es seguro el cambio de una cumarina a un ACOD en pacientes ancianos frágiles con FA? https://t.co/X8AQijGBEP ECA OJO!! https://t.co/urMyhM2pU5
RT @AlejandroLazo2: CLOT+ | Safety of Switching From a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older…
Safety of Switching From a Vitamin K Antagonist to a Non–Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial | Circulation https://t.co/v41WBZbs7k
CLOT+ | Safety of Switching From a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial. https://t.co/WMvsOMCfTe
RT @CircAHA: The randomized controlled trial Frail Atrial Fibrillation (#FRAIL-AF) showed that switching from vitamin K antagonists #VKA to…
Seguridad de pasar de un anticoagulante oral antagonista de vit K a uno no antagonista de vit K en ancianos frágiles con fibrilación auricular: resultados del ensayo controlado aleatorizado FRAIL-AF https://t.co/qEiNNju3d3 PMID 37634130
RT @CircAHA: The randomized controlled trial Frail Atrial Fibrillation (#FRAIL-AF) showed that switching from vitamin K antagonists #VKA to…
Por lo que hace énfasis en la necesidad de realizar una minuciosa evaluación del paciente al elegir entre continuar con AVK o cambiar a un ACOD en esta población. https://t.co/EGBDOQbN1D
RT @CircAHA: The randomized controlled trial Frail Atrial Fibrillation (#FRAIL-AF) showed that switching from vitamin K antagonists #VKA to…
RT @CircAHA: The randomized controlled trial Frail Atrial Fibrillation (#FRAIL-AF) showed that switching from vitamin K antagonists #VKA to…
RT @CircAHA: The randomized controlled trial Frail Atrial Fibrillation (#FRAIL-AF) showed that switching from vitamin K antagonists #VKA to…
RT @CircAHA: The randomized controlled trial Frail Atrial Fibrillation (#FRAIL-AF) showed that switching from vitamin K antagonists #VKA to…
RT @CircAHA: The randomized controlled trial Frail Atrial Fibrillation (#FRAIL-AF) showed that switching from vitamin K antagonists #VKA to…
RT @CircAHA: The randomized controlled trial Frail Atrial Fibrillation (#FRAIL-AF) showed that switching from vitamin K antagonists #VKA to…
RT @CircAHA: The randomized controlled trial Frail Atrial Fibrillation (#FRAIL-AF) showed that switching from vitamin K antagonists #VKA to…
RT @CircAHA: The randomized controlled trial Frail Atrial Fibrillation (#FRAIL-AF) showed that switching from vitamin K antagonists #VKA to…
RT @CircAHA: The randomized controlled trial Frail Atrial Fibrillation (#FRAIL-AF) showed that switching from vitamin K antagonists #VKA to…
RT @CircAHA: The randomized controlled trial Frail Atrial Fibrillation (#FRAIL-AF) showed that switching from vitamin K antagonists #VKA to…
RT @CircAHA: The randomized controlled trial Frail Atrial Fibrillation (#FRAIL-AF) showed that switching from vitamin K antagonists #VKA to…
RT @CircAHA: The randomized controlled trial Frail Atrial Fibrillation (#FRAIL-AF) showed that switching from vitamin K antagonists #VKA to…
RT @CircAHA: The randomized controlled trial Frail Atrial Fibrillation (#FRAIL-AF) showed that switching from vitamin K antagonists #VKA to…
RT @CircAHA: The randomized controlled trial Frail Atrial Fibrillation (#FRAIL-AF) showed that switching from vitamin K antagonists #VKA to…
RT @CircAHA: The randomized controlled trial Frail Atrial Fibrillation (#FRAIL-AF) showed that switching from vitamin K antagonists #VKA to…
RT @CircAHA: The randomized controlled trial Frail Atrial Fibrillation (#FRAIL-AF) showed that switching from vitamin K antagonists #VKA to…
RT @CircAHA: The randomized controlled trial Frail Atrial Fibrillation (#FRAIL-AF) showed that switching from vitamin K antagonists #VKA to…
RT @CircAHA: The randomized controlled trial Frail Atrial Fibrillation (#FRAIL-AF) showed that switching from vitamin K antagonists #VKA to…
RT @CircAHA: The randomized controlled trial Frail Atrial Fibrillation (#FRAIL-AF) showed that switching from vitamin K antagonists #VKA to…
RT @CircAHA: The randomized controlled trial Frail Atrial Fibrillation (#FRAIL-AF) showed that switching from vitamin K antagonists #VKA to…
RT @CircAHA: The randomized controlled trial Frail Atrial Fibrillation (#FRAIL-AF) showed that switching from vitamin K antagonists #VKA to…
RT @CircAHA: The randomized controlled trial Frail Atrial Fibrillation (#FRAIL-AF) showed that switching from vitamin K antagonists #VKA to…
RT @CircAHA: The randomized controlled trial Frail Atrial Fibrillation (#FRAIL-AF) showed that switching from vitamin K antagonists #VKA to…
RT @CircAHA: The randomized controlled trial Frail Atrial Fibrillation (#FRAIL-AF) showed that switching from vitamin K antagonists #VKA to…
RT @CircAHA: The randomized controlled trial Frail Atrial Fibrillation (#FRAIL-AF) showed that switching from vitamin K antagonists #VKA to…
RT @CircAHA: The randomized controlled trial Frail Atrial Fibrillation (#FRAIL-AF) showed that switching from vitamin K antagonists #VKA to…
RT @CircAHA: The randomized controlled trial Frail Atrial Fibrillation (#FRAIL-AF) showed that switching from vitamin K antagonists #VKA to…
RT @CircAHA: The randomized controlled trial Frail Atrial Fibrillation (#FRAIL-AF) showed that switching from vitamin K antagonists #VKA to…
RT @CircAHA: The randomized controlled trial Frail Atrial Fibrillation (#FRAIL-AF) showed that switching from vitamin K antagonists #VKA to…
RT @CircAHA: The randomized controlled trial Frail Atrial Fibrillation (#FRAIL-AF) showed that switching from vitamin K antagonists #VKA to…
RT @CircAHA: The randomized controlled trial Frail Atrial Fibrillation (#FRAIL-AF) showed that switching from vitamin K antagonists #VKA to…
RT @CircAHA: The randomized controlled trial Frail Atrial Fibrillation (#FRAIL-AF) showed that switching from vitamin K antagonists #VKA to…
RT @CircAHA: The randomized controlled trial Frail Atrial Fibrillation (#FRAIL-AF) showed that switching from vitamin K antagonists #VKA to…
RT @CircAHA: The randomized controlled trial Frail Atrial Fibrillation (#FRAIL-AF) showed that switching from vitamin K antagonists #VKA to…
RT @CircAHA: The randomized controlled trial Frail Atrial Fibrillation (#FRAIL-AF) showed that switching from vitamin K antagonists #VKA to…
RT @CircAHA: The randomized controlled trial Frail Atrial Fibrillation (#FRAIL-AF) showed that switching from vitamin K antagonists #VKA to…
RT @CircAHA: The randomized controlled trial Frail Atrial Fibrillation (#FRAIL-AF) showed that switching from vitamin K antagonists #VKA to…
RT @CircAHA: The randomized controlled trial Frail Atrial Fibrillation (#FRAIL-AF) showed that switching from vitamin K antagonists #VKA to…
RT @CircAHA: The randomized controlled trial Frail Atrial Fibrillation (#FRAIL-AF) showed that switching from vitamin K antagonists #VKA to…
RT @CircAHA: The randomized controlled trial Frail Atrial Fibrillation (#FRAIL-AF) showed that switching from vitamin K antagonists #VKA to…
RT @CircAHA: The randomized controlled trial Frail Atrial Fibrillation (#FRAIL-AF) showed that switching from vitamin K antagonists #VKA to…
RT @CircAHA: The randomized controlled trial Frail Atrial Fibrillation (#FRAIL-AF) showed that switching from vitamin K antagonists #VKA to…
RT @CircAHA: The randomized controlled trial Frail Atrial Fibrillation (#FRAIL-AF) showed that switching from vitamin K antagonists #VKA to…
RT @CircAHA: The randomized controlled trial Frail Atrial Fibrillation (#FRAIL-AF) showed that switching from vitamin K antagonists #VKA to…
RT @CircAHA: The randomized controlled trial Frail Atrial Fibrillation (#FRAIL-AF) showed that switching from vitamin K antagonists #VKA to…
The randomized controlled trial Frail Atrial Fibrillation (#FRAIL-AF) showed that switching from vitamin K antagonists #VKA to non-vitamin K oral anticoagulant #NOAC in frail older patients with AF was associated with more bleeding complications https://t.co/S1Q1nIcxoM https://t.co/x6RYs1YHf7
Should FRAIL AF, despite its limitations, give us pause about use of DOACs in frail older adults with AF?
RT @richardbuka: 1/ FRAIL-AF RCT of switch to DOAC or cont VKA in frail elderly with AF. VKA = better bleeding profile and no diff in strok…
1/ FRAIL-AF RCT of switch to DOAC or cont VKA in frail elderly with AF. VKA = better bleeding profile and no diff in stroke. Practice changing but many things to consider beyond what's in abstract. These were switchers, not newcomers! https://t.co/N5EB54WuFw
Mejores trabajos científicos 2023? ECLS SHOCK en SCA
RT @StrokeAHA_ASA: INTERVIEW: #BloggingStroke contributor @BraydonDymm interviews Dr. Geert-Jan Geersing on @CircAHA article "“Safety of Sw…
INTERVIEW: #BloggingStroke contributor @BraydonDymm interviews Dr. Geert-Jan Geersing on @CircAHA article "“Safety of Switching from a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients with Atrial Fibrillation.” https://t.co/todCvPAn5R https://t.co/JgLjDnn3lJ
@formsanitaria No tengo muy claro lo de recomendar en ancianos frágiles los de acción dirrcta despues de ver los resultados de warfarina en el ensayo FRAIL AF https://t.co/qSKTt0EzC4
RT @pedreiramicina: En este contexto surge en el seno de la Universidad de Utrecht una pregunta razonable: ¿Será acaso más seguro emplear A…
高齢心房細動患者(75歳以上、GFIスコア≥3)を対象とした試験で、VKAからNOACへの切り替えは、出血合併症リスクが高く、血栓塞栓性合併症の減少とは関連しないことが明らかになりました https://t.co/QRysiouR2Q
FRAIL-AF RCT https://t.co/6d6aO2obAP BOTTOM LINE: If patients are doing well on warfarin, switching to DOAC should be AVOIDED unless there is another strong compelling reason. https://t.co/oKcDLUhh0Y
RT @pedreiramicina: En este contexto surge en el seno de la Universidad de Utrecht una pregunta razonable: ¿Será acaso más seguro emplear A…
https://t.co/JLa1hbw3go 出血性合併症 VKA→DOAC切り替え vs VKA継続:HR1.69(95%CI 1.23-2.32) 血栓塞栓イベント有意差なし VKAはワルファリンではないらしい https://t.co/bEvaAHXxvG
RT @pedreiramicina: En este contexto surge en el seno de la Universidad de Utrecht una pregunta razonable: ¿Será acaso más seguro emplear A…
En este contexto surge en el seno de la Universidad de Utrecht una pregunta razonable: ¿Será acaso más seguro emplear ACOD en pacientes ancianos frágiles por riesgo de sangrado? Link al ensayo: https://t.co/aT694wt1TO https://t.co/QMNPWCRzjj
RT @ProfMakris: Switching frail elderly patients from VKA antagonists to DOACs resulted in a significantly higher rate of bleeding. Dutch R…
RT @toki_wo_koe: JCでのまとめをつらつら。 これまでの、各DOACのlandmark study結果から、出血の観点から「DOAC>VKA」という流れは間違いない。 しかし、実臨床やっていると、フレイリティの高い高齢A-fib患者の抗凝固って困る。過去のRC…
RT @toki_wo_koe: JCでのまとめをつらつら。 これまでの、各DOACのlandmark study結果から、出血の観点から「DOAC>VKA」という流れは間違いない。 しかし、実臨床やっていると、フレイリティの高い高齢A-fib患者の抗凝固って困る。過去のRC…
JCでのまとめをつらつら。 これまでの、各DOACのlandmark study結果から、出血の観点から「DOAC>VKA」という流れは間違いない。 しかし、実臨床やっていると、フレイリティの高い高齢A-fib患者の抗凝固って困る。過去のRCTでは除外されているポピュレーション #循薬ネット https://t.co/ox4ew2zVjl https://t.co/ZF5NFOv0Em
RT @ProfMakris: Switching frail elderly patients from VKA antagonists to DOACs resulted in a significantly higher rate of bleeding. Dutch R…
RT @ProfMakris: Switching frail elderly patients from VKA antagonists to DOACs resulted in a significantly higher rate of bleeding. Dutch R…
RT @ProfMakris: Switching frail elderly patients from VKA antagonists to DOACs resulted in a significantly higher rate of bleeding. Dutch R…
RT @ProfMakris: Switching frail elderly patients from VKA antagonists to DOACs resulted in a significantly higher rate of bleeding. Dutch R…
RT @ProfMakris: Switching frail elderly patients from VKA antagonists to DOACs resulted in a significantly higher rate of bleeding. Dutch R…
RT @ProfMakris: Switching frail elderly patients from VKA antagonists to DOACs resulted in a significantly higher rate of bleeding. Dutch R…
Outcomes of switching frail patients to DOACs …not too soon https://t.co/2Swft2RhLm
RT @ProfMakris: Switching frail elderly patients from VKA antagonists to DOACs resulted in a significantly higher rate of bleeding. Dutch R…
RT @ProfMakris: Switching frail elderly patients from VKA antagonists to DOACs resulted in a significantly higher rate of bleeding. Dutch R…
RT @ProfMakris: Switching frail elderly patients from VKA antagonists to DOACs resulted in a significantly higher rate of bleeding. Dutch R…
RT @BITNavarra: Cambio de un anticoagulante anti-vitamina K (AVK) a un anticoagulante de acción directa (ACOD) en pacientes ancianos frágil…
RT @ProfMakris: Switching frail elderly patients from VKA antagonists to DOACs resulted in a significantly higher rate of bleeding. Dutch R…
RT @ProfMakris: Switching frail elderly patients from VKA antagonists to DOACs resulted in a significantly higher rate of bleeding. Dutch R…
RT @ProfMakris: Switching frail elderly patients from VKA antagonists to DOACs resulted in a significantly higher rate of bleeding. Dutch R…
RT @ProfMakris: Switching frail elderly patients from VKA antagonists to DOACs resulted in a significantly higher rate of bleeding. Dutch R…
RT @ProfMakris: Switching frail elderly patients from VKA antagonists to DOACs resulted in a significantly higher rate of bleeding. Dutch R…
RT @ProfMakris: Switching frail elderly patients from VKA antagonists to DOACs resulted in a significantly higher rate of bleeding. Dutch R…
RT @ProfMakris: Switching frail elderly patients from VKA antagonists to DOACs resulted in a significantly higher rate of bleeding. Dutch R…
RT @ProfMakris: Switching frail elderly patients from VKA antagonists to DOACs resulted in a significantly higher rate of bleeding. Dutch R…
RT @ProfMakris: Switching frail elderly patients from VKA antagonists to DOACs resulted in a significantly higher rate of bleeding. Dutch R…
RT @ProfMakris: Switching frail elderly patients from VKA antagonists to DOACs resulted in a significantly higher rate of bleeding. Dutch R…
RT @ProfMakris: Switching frail elderly patients from VKA antagonists to DOACs resulted in a significantly higher rate of bleeding. Dutch R…
RT @ProfMakris: Switching frail elderly patients from VKA antagonists to DOACs resulted in a significantly higher rate of bleeding. Dutch R…
RT @ProfMakris: Switching frail elderly patients from VKA antagonists to DOACs resulted in a significantly higher rate of bleeding. Dutch R…
RT @ProfMakris: Switching frail elderly patients from VKA antagonists to DOACs resulted in a significantly higher rate of bleeding. Dutch R…
RT @ProfMakris: Switching frail elderly patients from VKA antagonists to DOACs resulted in a significantly higher rate of bleeding. Dutch R…
RT @ProfMakris: Switching frail elderly patients from VKA antagonists to DOACs resulted in a significantly higher rate of bleeding. Dutch R…
RT @ProfMakris: Switching frail elderly patients from VKA antagonists to DOACs resulted in a significantly higher rate of bleeding. Dutch R…
Switching frail elderly patients from VKA antagonists to DOACs resulted in a significantly higher rate of bleeding. Dutch RCT published in @circulation. https://t.co/iEoDlVgr7V https://t.co/NRVLp4BTdS
対象論文 https://t.co/fQv805EzKQ
@yourheartdoc1 @medmalreviewer https://t.co/l7YySdrVkU
Switching from warfarin to a DOAC in older adults (>75 years) with frailty and #afib may be associated with an increased risk of bleeding, without any difference in thrombotic events. @CircAHA https://t.co/8NZUjZHJxy
対象論文 は、これ。 https://t.co/ox4ew2zVjl
RT @Cardio_Pharm_JP: 対象論文: https://t.co/fQv805EzKQ ビタミン K アンタゴニスト (VKA) で管理されている心房細動 (AF) のフ高齢フレイル患者を非ビタミン K 経口抗凝固薬 (NOAC) に切り替えるべきかどうかの検…
対象論文: https://t.co/fQv805EzKQ ビタミン K アンタゴニスト (VKA) で管理されている心房細動 (AF) のフ高齢フレイル患者を非ビタミン K 経口抗凝固薬 (NOAC) に切り替えるべきかどうかの検討です。 こんな患者さんばっかりじゃないですか?対象症例群の背景とか気になります
@jfdwolff @EileenBurns13 @cpgale3 Biggest area of harm reduction is cessation of unnecessarily prolonged DAPT use - certainly v. limited role beyond 12m, and probably 3m. Though the data are missing. The FRAIL-AF study teaches us that just because you feel good, doesn't make you right. https://t.co/bZN4AQIJEs 3/n
RT @HRSonline: NEW EPISODE OF THE LEAD! [Ep. 28] A Discussion of Safety of Switching from a Vitamin K Antagonist to a Non-Vitamin K Antago…
RT @HRSonline: NEW EPISODE OF THE LEAD! [Ep. 28] A Discussion of Safety of Switching from a Vitamin K Antagonist to a Non-Vitamin K Antago…
RT @HRSonline: NEW EPISODE OF THE LEAD! [Ep. 28] A Discussion of Safety of Switching from a Vitamin K Antagonist to a Non-Vitamin K Antago…
NEW EPISODE OF THE LEAD! [Ep. 28] A Discussion of Safety of Switching from a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients with Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial
RT @FarmaMadridAP: (Circulation) Resultados de seguridad en el intercambio de anticoagulante oral anti-vitamina K (AVK) a anticoagulante di…
RT @FarmaMadridAP: (Circulation) Resultados de seguridad en el intercambio de anticoagulante oral anti-vitamina K (AVK) a anticoagulante di…
@vmuecke_k @yannik_munich Diese Leitlinien werden weiter unterstüzt durch die Erkenntnisse der neulich publizierten Studie FRAIL-AF, in der Patienten die auf NOAK umgestellt wurden, häufiger Blutungen erlitten haben: https://t.co/LMnqWEOJWj
RT @vmuecke_k: „Marcumar ist doch old school. Das gibt man nicht mehr!“ Oft von jüngeren Klinikärzte:innen gehört, stimmt aber nicht! Be…
RT @vmuecke_k: „Marcumar ist doch old school. Das gibt man nicht mehr!“ Oft von jüngeren Klinikärzte:innen gehört, stimmt aber nicht! Be…
RT @vmuecke_k: „Marcumar ist doch old school. Das gibt man nicht mehr!“ Oft von jüngeren Klinikärzte:innen gehört, stimmt aber nicht! Be…
RT @vmuecke_k: „Marcumar ist doch old school. Das gibt man nicht mehr!“ Oft von jüngeren Klinikärzte:innen gehört, stimmt aber nicht! Be…
RT @vmuecke_k: „Marcumar ist doch old school. Das gibt man nicht mehr!“ Oft von jüngeren Klinikärzte:innen gehört, stimmt aber nicht! Be…
Safety of Switching from a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients with Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial | Circulation https://t.co/YauFBF4Mh7
به نظرم اين مطالعه مهمترين مطالعه ي مطرح شده در كنگره ي قلب اروپا باشه. نتايج با اون چيزي كه فكر مي كرديم خيلي فرق داره. https://t.co/2B7pyXJBLv
RT @elmir1omerovic: Safety of Switching from a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patient…
Safety of Switching from a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients with Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial | Circulation https://t.co/NOyW6KLiJw What does this trial teach us?
Safety of Switching from a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Pat… https://t.co/ayBC1mRQ1l
RT @syaddana_neuro: Safety of Switching from a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patient…
【RCT】フレイルのある75歳以上の心房細動患者へのINRガイド下VKAからDOACへの切り替えは、VKAの継続と比較して、大出血または臨床的に重要な非大出血を増加させた。(無益性により中止) #ペ読 https://t.co/juzaO2aMst
Take a look at this paper from Read by QxMD: Safety of Switching from a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients with Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial: No Switch https://t.co/KdXX96RVQa https://t.co/nhfciqmyvw
Safety of Switching from a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients with Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial | Circulation https://t.co/xCCF2hox6b
RT @hematogeriatria: Safety of Switching from a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patien…
Safety of Switching from a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients with Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial | Circulation https://t.co/qsCXDBYNya
RT @danisevisan:
Safety of Switching from a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients with Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial | Circulation https://t.co/MhbCbg34Gm
Safety of Switching from a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients with Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial https://t.co/0VWSZf8lUH
La importancia de valorar el perfil del paciente en la toma de decisiones Safety of Switching from a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients with Atrial Fibrillation: Results of the FRAIL-AF Circulation https://t.co/touXuM2txN
RT @danisevisan:
RT @hematogeriatria: Safety of Switching from a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patien…
Safety of Switching from a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients with Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial | Circulation https://t.co/DEtREUjCfN
RT @syaddana_neuro: Safety of Switching from a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patient…
RT @syaddana_neuro: Safety of Switching from a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patient…
Mucho cuidado en cambiar de anticoagulante en pacientes >75 años. Si viene bien con warfarínicos, dejémoslo así. Safety of Switching from a Vitamin K Antagonist to a Non-Vitamin K Antagonist in Frail Older Patients with AF: Results of the FRAIL-AF RCT https://t.co/N1kTg2ronH
Safety of Switching from a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients with Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial | Circulation https://t.co/eLsrzDvsud
Safety of Switching from a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients with Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial | Circulation https://t.co/VLBGempmQL
ESC関連の中ではこの研究が気になりました。 Safety of Switching from a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients with Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial |https://t.co/1L3WzkW67H
https://t.co/lTXBGab0vV Safety of Switching from a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in #Frail Older Patients with #AtrialFibrillation: Results of the FRAIL-AF Randomized Controlled Trial - worth a read! @ProfDConnelly recommended @PHanlon17
BH